Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol-lowering therapy: is there really a controversy?

P W Jungnickel1

  • 1Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha 68198, USA. PJUNGNIC@UNMC.EDU

The Annals of Pharmacotherapy
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pantoprazole: a new proton pump inhibitor.

Clinical therapeutics·2000
Same author

Opportunities for pharmacy specialists as the delivery of health care changes.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

Evaluation of community pharmacists' experiences with cholesterol screening programs.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·1998
Same author

Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.

Journal of general internal medicine·1997
Same author

Pharmacoepidemiology of niacin.

Annals of internal medicine·1995
Same author

Blind comparison of patient preference for Flavored Colestid Granules and Questran Light.

The Annals of pharmacotherapy·1993
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Managing high cholesterol is becoming clearer, not gray. Advances in understanding atherosclerosis and new potent therapies offer significant benefits for preventing coronary heart disease events, especially in secondary prevention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Hypercholesterolemia management recommendations are evolving.
  • Increasing knowledge of atherogenesis and thromboembolic events.
  • Cholesterol's role in coronary events is better understood.

Discussion:

  • Newer cholesterol-lowering agents are more potent.
  • Substantial reductions in cholesterol levels are more achievable.
  • Understanding of therapy benefits in diverse patient groups is improving.

Key Insights:

  • Cholesterol-lowering therapy significantly impacts coronary heart disease (CHD).
  • Effective in preventing recurrent events and reducing mortality in secondary prevention.
  • Many patients benefit significantly from cholesterol-lowering drugs.

Related Experiment Videos

Outlook:

  • Further research needed, particularly for women and older patients.
  • Clinicians should continue to prescribe beneficial cholesterol-lowering therapies.
  • Continued advancements in understanding and treating hypercholesterolemia.